Jardiance FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 17, 2022.
FDA Approved: Yes (First approved August 1, 2014)
Brand name: Jardiance
Generic name: empagliflozin
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction, Heart Failure
Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor used for the treatment of type 2 diabetes; and to reduce the risk of cardiovascular death in patients with heart failure, and type 2 diabetes patients with established cardiovascular disease.
Jardiance is indicated:
- to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development timeline for Jardiance
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.